Four Latin American countries digitised their health systems. Tech was the easy part.

Digital health transformation is one of the most heavily funded categories in global health policy and one of the least studied at the point where it actually happens. The literature is dense with strategy documents and thin on accounts of what occurred after the strategy was signed. A study published on 27 August is an attempt at the second thing [s1].

Four countries, thirty-two interviews

Researchers conducted a multiple case study of national digital health transformation policy implementation in Uruguay, Argentina, Chile and Mexico, based on 32 semi-structured interviews. The four were selected for their diversity in governance structures and their different stages of digital health transformation [s1].

This is qualitative work and should be read as such: 32 interviews across four countries cannot support a claim about how often anything happens, and the study does not attempt one. What it can do is identify which factors participants in the process consistently identified as decisive.

Those factors, as the authors report them, were the interaction of policy objectives, technical and financial conditions, organisational and political dynamics, and implementation capacities [s1]. The elements associated with progress were clear definitions of problems; coherent, context-sensitive implementation strategies; strong multisectoral teams; sustained leadership; capacity-building efforts; and robust governance frameworks [s1].

Notice what is absent from that list. No specific technology, no architectural standard, no vendor. The authors' conclusion states it directly: effective implementation depends not only on the technical aspects of the policy but on the coherence and institutional adoption of clear policy objectives in different contexts [s1].

Their framing of the failure mode is the sharper part. Digital health transformation, they argue, should be viewed as a strategic means to improve health system performance rather than as an end in itself [s1]. That is a description of something that evidently happens — programmes whose success metric becomes deployment rather than performance.

Where the products are being built

A second paper, published 31 August, approaches the same inequity from the supply side. Its authors examined 1,672 patents filed with the United States Patent and Trademark Office and 7,439 clinical trials registered on ClinicalTrials.gov between 2011 and 2025, analysing patterns with large language models, network analysis and the Bass diffusion model [s2].

The pattern they describe: developed economies demonstrate broad coverage across therapeutic areas and technologies, positioning themselves as key innovators, whereas less developed economies tend to concentrate on underserved conditions with engagement limited to established technologies [s2].

Both halves of that sentence matter. Lower-income countries are not absent from digital therapeutics development — they are working on conditions the wealthy pipeline neglects. But they are doing so with older technology, which is a durable disadvantage rather than a temporary one.

The methodological caution

The patent analysis inherits a structural bias worth naming: it counts filings at the United States patent office, which is a measure of intent to commercialise in the US market as much as a measure of innovation. Development that never seeks US protection does not appear. ClinicalTrials.gov has a similar skew, being a US registry that many but not all trials worldwide use. The authors' framing acknowledges the underlying problem — that global analyses of digital therapeutics often overlook patterns in middle- and low-income countries [s2] — and their data source is itself an example of why.

Neither study measures a health outcome. The Latin American case studies describe implementation processes, not the performance of the systems implemented [s1]. The patent and trial analysis describes where development activity is concentrated, not whether any of it works [s2].

What follows

The two papers point at the same gap from opposite ends. One finds that the constraint on implementation is institutional — governance, leadership, multisectoral capacity — rather than technical [s1]. The other finds that the technology being developed for lower-income settings is older and narrower than what is being developed elsewhere [s2].

The authors of the second paper call for international collaboration and for strategies tailored to different economic contexts [s2]. The first paper is, in effect, a description of what such tailoring requires on the receiving end, and it is not a procurement problem.

What to watch is whether any of the four national programmes publishes performance data — not adoption counts, but the health system performance improvements the policies were justified by. On the evidence of these case studies, that measurement is the thing most likely to be skipped.

Sources

• [s1] Implementing digital health transformation policies in Latin America: insights from four national case studies. npj Digital Medicine, 27 August 2026. https://doi.org/10.1038/s41746-026-03129-9
• [s2] Analysis of digital therapeutics patterns by economic level: evidence from the United States Patents and Trademark Offices and ClinicalTrials.gov. npj Digital Medicine, 31 August 2026. https://doi.org/10.1038/s41746-026-03146-8